Open access · CC-BY
via OpenAlex
Combining DNA damaging therapeutics with immunotherapy: more haste, less speed
Jessica S. Brown, Raghav Sundar, Juanita Suzanne Lopez
British Journal of Cancer · 2017 · ▲ 233 citations
Abstract
The idea that chemotherapy can be used in combination with immunotherapy may seem somewhat counterproductive, as it can theoretically eliminate the immune cells needed for antitumour immunity. However, much preclinical work has now demonstrated that in addition to direct cytotoxic effects on cancer cells, a proportion of DNA damaging agents may actually promote immunogenic cell death, alter the inflammatory milieu of the tumour microenvironment and/or stimulate neoantigen production, thereby activating an antitumour immune response. Some notable combinations have now moved forward into the clinic, showing promise in phase I-III trials, whereas others have proven toxic, and challenging to deliver. In this review, we discuss the emerging data of how DNA damaging agents can enhance the immunogenic properties of malignant cells, focussing especially on immunogenic cell death, and the expansion of neoantigen repertoires. We discuss how best to strategically combine DNA damaging therapeutics with immunotherapy, and the challenges of successfully delivering these combination regimens to patients. With an overwhelming number of chemotherapy/immunotherapy combination trials in process, clear hypothesis-driven trials are needed to refine the choice of combinations, and determine the timing and sequencing of agents in order to stimulate antitumour immunological memory and improve maintained durable response rates, with minimal toxicity.
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- OpenAlex
- DOI
- 10.1038/bjc.2017.376
- Canonical
- link ↗
- Fetched
- 2026-09-29 MST
Cite this
APA
Brown, J.S., Sundar, R., & Lopez, J.S. (2017). Combining DNA damaging therapeutics with immunotherapy: more haste, less speed. <em>British Journal of Cancer</em>. https://doi.org/10.1038/bjc.2017.376
Vancouver
Brown JS, Sundar R, Lopez JS. Combining DNA damaging therapeutics with immunotherapy: more haste, less speed. British Journal of Cancer. 2017. doi:10.1038/bjc.2017.376.
BibTeX
@article{jessica2017Combin,
title = {Combining DNA damaging therapeutics with immunotherapy: more haste, less speed},
author = {Jessica S. Brown and Raghav Sundar and Juanita Suzanne Lopez},
journal = {British Journal of Cancer},
year = {2017},
doi = {10.1038/bjc.2017.376},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
Genome Medicine 2023
Open access · CC-BY
Tumor microenvironment remodeling after neoadjuvant immunotherapy in non-small cell lung cancer revealed by single-cell RNA sequencing
Cell Metabolism 2023
Preprint · OA
Mitohormesis
Clinical & Experimental Immunology 2005
Preprint · OA
Age-associated deficiency in activation-induced up-regulation of telomerase activity in CD4+ T cells
Versailles Hospital 2012
Open access · US-GOV
An Observatory for Patients Aged 55 Years and Over With Philadelphia Chromosome Positive (Ph+ or BCR-ABL+) Acute Lymphoblastic Leukemia (ALL) and Treated With the Combination of Tyrosine Kinase Inhibitors and Low Intensity Chemotherapy.
Gut 2011
Citation only
Autologous bone marrow-derived mesenchymal stromal cells in the treatment of fistulising Crohn's disease
Microbiome 2018
Open access · CC-BY